We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Breath Test Determines Treatment for Chronic Cough

By HospiMedica staff writers
Posted on 25 Sep 2006
A simple, inexpensive breath test determines whether inhaled corticosteroids will relieve a patient's chronic cough.

The exhaled nitric oxide test measures inflammation in the lungs' bronchial tubes. More...
The patient breathes into an analyzer four or five times over the course of 10 minutes. Abnormal scores indicate that the patient has asthma or possibly non-asthmatic eosinophilic bronchitis. Both conditions can be effectively treated with inhaled corticosteroids. In these patients, inflammation irritates the airway and prompts coughing. Corticosteroids help reduce the inflammation, alleviating the cough.

This test is much easier for patients and predicts response to corticosteroid treatment better than the commonly used test, the methacholine challenge, according to Peter Hahn, M.D., a pulmonologist at the Mayo Clinic (Rochester, MN, USA). A study was conducted via chart review of consecutive patients evaluated at Mayo Clinic for chronic cough using both exhaled nitric oxide and methacholine challenge testing between December 2004 and November 2005. Results were presented in an abstract presented at the European Respiratory Society Meeting in Munich (Germany) in September 2006.

"Patients with a positive, or abnormal, exhaled nitric oxide test had a strong likelihood of response to inhaled corticosteroids, whereas a negative, or normal, exhaled nitric oxide test virtually excluded response to the medication,” said Dr. Hahn. "The accuracy of the exhaled nitric oxide test in predicting response to inhaled corticosteroids for chronic cough appears to be better than with methacholine-challenge testing. This may potentially have a significant impact on how patients with chronic cough are evaluated and treated.”

Dr Hahn said that the next step needed in testing for chronic cough is a prospective study comparing the utility of the methacholine challenge versus the exhaled nitric oxide test.



Related Links:
Mayo Clinic

Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Digital X-Ray Detector Panel
Acuity G4
Autoclave
Advance
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.